Payment overview · 2025
General Payments
$124.77
7 reported records · 3 companies
Healthcare provider profile · identity verified
Pamela Jones, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · IRVINE, KY · NPI 1205807849
Verified facts
What the public records show
CMS Open Payments records show Pamela Jones, APRN received $124.77 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 58.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.06 | 58.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.74 | 26.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.97 | 15.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.77 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.32 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.74 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
96 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 715 | 148 |
| Omeprazole | Omeprazole | 683 | 138 |
| Gabapentin | Gabapentin | 623 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 93 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 548 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 97 |
| Lisinopril | Lisinopril | 422 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 393 | 74 |
| Furosemide | Furosemide | 335 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 56 |
| Carvedilol | Carvedilol | 278 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 266 | 59 |
| Glipizide Er | Glipizide | 234 | 49 |
| Alprazolam | Alprazolam | 233 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 37 |
| Sertraline Hcl | Sertraline Hcl | 206 | 36 |
| Metformin Hcl | Metformin Hcl | 204 | 42 |
| Losartan Potassium | Losartan Potassium | 195 | 41 |
| Methylprednisolone | Methylprednisolone | 194 | 150 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 33 |
| Famotidine | Famotidine | 175 | 51 |
| Ozempic | Semaglutide | 171 | 31 |
| Glipizide | Glipizide | 170 | 28 |
| Cefdinir | Cefdinir | 160 | 116 |
| Promethazine Hcl | Promethazine Hcl | 156 | 24 |
| Eliquis | Apixaban | 152 | 31 |
| Celecoxib | Celecoxib | 141 | 27 |
| Potassium Chloride | Potassium Chloride | 137 | 36 |
| Prednisone | Prednisone | 136 | 89 |
| Mounjaro | Tirzepatide | 135 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 135 | 51 |
| Montelukast Sodium | Montelukast Sodium | 131 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 25 |
| Trazodone Hcl | Trazodone Hcl | 125 | 23 |
| Allopurinol | Allopurinol | 118 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 117 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 19 |
| Azithromycin | Azithromycin | 106 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 25 |
| Ibuprofen | Ibuprofen | 104 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 26 |
| Buspirone Hcl | Buspirone Hcl | 97 | 15 |
| Clonazepam | Clonazepam | 97 | 15 |
| Januvia | Sitagliptin Phosphate | 97 | 24 |
| Jardiance | Empagliflozin | 96 | 23 |
| Meloxicam | Meloxicam | 94 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 19 |
| Tramadol Hcl | Tramadol Hcl | 93 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 23 |
| Estradiol | Estradiol | 89 | 21 |
| Levofloxacin | Levofloxacin | 89 | 70 |
| Amoxicillin | Amoxicillin | 85 | 63 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 14 |
| Fluconazole | Fluconazole | 82 | 46 |
| Meclizine Hcl | Meclizine Hcl | 82 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 74 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 18 |
| Pregabalin | Pregabalin | 72 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 50 |
| Diazepam | Diazepam | 68 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 68 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Simvastatin | Simvastatin | 68 | 17 |
| Nystatin | Nystatin | 67 | 36 |
| Spironolactone | Spironolactone | 66 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 65 | 17 |
| Topiramate | Topiramate | 64 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 61 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 13 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 47 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 14 |
| Lorazepam | Lorazepam | 56 | 12 |
| Atenolol | Atenolol | 54 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 52 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 51 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 11 |
| Synthroid | Levothyroxine Sodium | 50 | 12 |
| Ondansetron Odt | Ondansetron | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | suppressed |
| Linzess | Linaclotide | 48 | 11 |
| Valsartan | Valsartan | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 11 |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 11 |
| Nitroglycerin | Nitroglycerin | 45 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 36 |
| Cephalexin | Cephalexin | 43 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 42 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Chlorthalidone | Chlorthalidone | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 26 |
| Clonidine Hcl | Clonidine Hcl | 34 | 11 |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Ibu | Ibuprofen | 31 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 27 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 16 |
| Metronidazole | Metronidazole | 24 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Xiidra | Lifitegrast | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.77 · 7 records | ABBVIE INC. | GEMTESA, MOUNJARO, QULIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error